This comprehensive review outlines current strategies for atrial fibrillation management, emphasizing rate versus rhythm control and the increasing role of novel oral anticoagulants for stroke prevention.
This review summarizes the current management of atrial fibrillation, including advances in anticoagulation, NOACs, reversal agents, and nonpharmacological therapies.
Atrial fibrillation (AF) is the most commonly encountered arrhythmia in clinical practice. Aging populations coupled with improved outcomes for many chronic medical conditions has led to increases in AF diagnoses. AF is also known to be associated with an increased risk of adverse events such as transient ischemic attack, ischemic stroke, systemic embolism, and death. This association is enhanced in select populations with preexisting comorbid conditions such as chronic heart failure. The aim of this review is to highlight the advances in the field of cardiology in the management of AF in both acute and long-term settings. We will also review the evolution of anticoagulation management over the past few years and landmark trials in the development of novel oral anticoagulants (NOACs), reversal agents for new NOACs, nonpharmacological options to anticoagulation therapy, and the role of implantable loop recorder in AF management.
Amin et al. (Fri,) conducted a review in Atrial fibrillation. This comprehensive review outlines current strategies for atrial fibrillation management, emphasizing rate versus rhythm control and the increasing role of novel oral anticoagulants for stroke prevention.